NYSEAMERICAN:VNRX VolitionRx - VNRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. $1.91 -0.01 (-0.52%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.88▼$1.9650-Day Range N/A52-Week Range$1.31▼$3.30Volume68,966 shsAverage Volume150,811 shsMarket Capitalization$111.05 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media VolitionRx MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside196.7% Upside$5.67 Price TargetShort InterestHealthy1.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$409,500 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.3 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, VolitionRx has a forecasted upside of 196.7% from its current price of $1.91.Amount of Analyst CoverageVolitionRx has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.39% of the float of VolitionRx has been sold short.Short Interest Ratio / Days to CoverVolitionRx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VolitionRx has recently decreased by 6.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $409,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.00% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.30% of the stock of VolitionRx is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for VolitionRx are expected to remain at ($0.58) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVolitionRx has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About VolitionRx (NYSEAMERICAN:VNRX) StockVolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.Read More Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Stock News HeadlinesMarch 21, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for VolitionRX (VNRX)March 20, 2023 | benzinga.comVolitionRX Stock (AMEX:VNRX), Guidance and ForecastApril 1, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 10, 2023 | finance.yahoo.comVolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business UpdateMarch 6, 2023 | finance.yahoo.comVolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9thFebruary 27, 2023 | finance.yahoo.comVNRX: Nu.Q Vet Cancer Test Being Launched by Supply Agreement Partners Heska and IDEXX; 4.945 million Share Offering Completed to Help Fund Management’s InitiativesFebruary 22, 2023 | finance.yahoo.comVolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common StockFebruary 17, 2023 | finance.yahoo.comVolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common StockApril 1, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 16, 2023 | finance.yahoo.comVolition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska CorporationJanuary 8, 2023 | finance.yahoo.comVolition Issues Business Review 2022November 14, 2022 | finance.yahoo.comVolitionRx Limited Announces Third Quarter 2022 Financial Results and Business UpdateNovember 14, 2022 | finance.yahoo.comVolition Announces Clinical Research Study with OncovetNovember 10, 2022 | finance.yahoo.comVolition to Participate in a Lung Cancer Screening Study in FranceOctober 20, 2022 | benzinga.comVolition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test - VolitionRX (AMEX:VNRX) - BenzingaOctober 20, 2022 | nasdaq.comVolitionRx Signs Global Supply Deal For Nu.Q Vet Cancer Test - NasdaqOctober 20, 2022 | finance.yahoo.comVolition Signs Global Supply Agreement for Nu.Q® Vet Cancer TestOctober 11, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo FinanceSeptember 12, 2022 | proactiveinvestors.comNA Proactive news snapshot: Unrivaled Brands, Steppe Gold, Quantum eMotion, First Mining Gold, Co-Diagnostics, Doré Copper Mining, Todos Medical UPDTE... - Proactive Investors USASeptember 12, 2022 | globenewswire.comVolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th - GlobeNewswireAugust 16, 2022 | finance.yahoo.comVolition Appoints Mickie Henshall as an Independent DirectorAugust 11, 2022 | greenwichtime.comVolitionRX: Q2 Earnings Snapshot - Greenwich TimeAugust 11, 2022 | proactiveinvestors.comVolitionRX announces 2nd quarter financials as company look to accelerate growth - Proactive Investors USAAugust 11, 2022 | seekingalpha.comVolitionRX Q2 2022 Earnings Preview (NYSE:VNRX) - Seeking AlphaAugust 10, 2022 | proactiveinvestors.comNA Proactive news snapshot: Banxa Holdings, Xeris Biopharma, VolitionRx Limited, TRACON Pharmaceuticals, Etruscus Resources UPDATE ... - Proactive Investors USAAugust 10, 2022 | seekingalpha.comVolitionRX reports Q2 results (NYSE:VNRX) - Seeking AlphaAugust 10, 2022 | finance.yahoo.comVolitionRx Limited Announces Second Quarter 2022 Financial Results and Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Company Calendar Last Earnings11/10/2021Today4/01/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:VNRX Previous SymbolNYSEMKT:VNRX CUSIPN/A CIKN/A Webwww.volitionrx.com Phone(646) 650-1351Fax65 32 8172 5651Employees65Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.67 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+196.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,820,000.00 Net Margins-15,452.74% Pretax Margin-15,607.46% Return on Equity-350.45% Return on Assets-116.26% Debt Debt-to-Equity Ratio0.94 Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$90,000.00 Price / Sales1,233.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book5.79Miscellaneous Outstanding Shares58,140,000Free Float48,838,000Market Cap$111.05 million OptionableNot Optionable Beta1.73 Key ExecutivesCameron John ReynoldsPresident, Chief Executive Officer & DirectorGaetan MichelChief Operating OfficerTerig HughesChief Financial Officer & TreasurerJacob Vincent MicallefChief Scientific OfficerTerry KellyChief Innovation OfficerKey CompetitorsAchieve Life SciencesNASDAQ:ACHVAlpha TeknovaNASDAQ:TKNOMyMD PharmaceuticalsNASDAQ:MYMDAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCView All CompetitorsInsiders & InstitutionsGuy Archibald InnesBought 234,000 shares on 2/22/2023Total: $409,500.00 ($1.75/share)Lagoda Investment Management L.P.Bought 498,300 shares on 2/15/2023Ownership: 6.553%Morgan StanleySold 126,458 shares on 2/15/2023Ownership: 0.440%Cerity Partners LLCBought 38,026 shares on 2/15/2023Ownership: 0.066%Susquehanna International Group LLPSold 6,200 shares on 2/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VNRX Stock - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price forecast for 2023? 3 analysts have issued 1-year price targets for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 196.7% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. When is VolitionRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our VNRX earnings forecast. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSEAMERICAN:VNRX) released its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. VolitionRx had a negative net margin of 15,452.74% and a negative trailing twelve-month return on equity of 350.45%. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Protalix BioTherapeutics (PLX), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC). What is VolitionRx's stock symbol? VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX." How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VolitionRx's stock price today? One share of VNRX stock can currently be purchased for approximately $1.91. How much money does VolitionRx make? VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $111.05 million and generates $90,000.00 in revenue each year. The medical research company earns $-26,820,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. How can I contact VolitionRx? VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651. This page (NYSEAMERICAN:VNRX) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.